Status:
COMPLETED
Antithrombin III and Post-liver Transplantation Acute Kidney Injury
Lead Sponsor:
Asan Medical Center
Conditions:
Liver Transplantation and Antithrombin
Eligibility:
All Genders
19+ years
Brief Summary
The reno-protective effect of Antithrombin III (ATIII) has been well-studied in various animal studies; however, little is known about the effect of ATIII on kidney function in patients undergoing liv...
Eligibility Criteria
Inclusion
- patients who underwent either living- or deceased-donor LT (LDLT, DDLT) from January 2010 to January 2018
Exclusion
- patients who underwent re-transplantation
- patients who were previously diagnosed with end-stage renal disease or Chronic kidney disease
- patients who were being treated with continuous renal replacement therapy
- preoperative or postoperative Antithrombin III levels were not available
Key Trial Info
Start Date :
January 4 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
2395 Patients enrolled
Trial Details
Trial ID
NCT04912193
Start Date
January 4 2010
End Date
December 31 2019
Last Update
June 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 05507